[Primary prevention of cerebral toxoplasmosis in patients with HIV infection: results of a double-blind randomized trial, pyrimethamine versus placebo].
To assess the efficacy of pyrimethamine (Pyr) for primary prophylaxis of cerebral toxoplasmosis (CT) in HIV patients (pts), 554 pts were randomized in a double-blind, placebo-controlled trial (mean follow-up: 14 months). The intent-to-treat analysis found no significant difference in the incidence of ct at 1 year: 12% (Pyr) versus 13% (Pcb) nor in survival. Side-effects leading to stop the study drug were more frequent in Pyr group, especially cutaneous rashes: 8% (Pyr) versus 2% (Pcb).
Morlat
P
P
Service de médecine interne, hôpital Saint-André, Bordeaux.
Chene
G
G
Leport
C
C
Rousseau
F
F
Luft
B
B
Aubertin
J
J
Hafner
R
R
Salamon
R
R
Vilde
J L
JL
D004311:Double-Blind Method; D015658:HIV Infections / Q000150:complications*; D015497:HIV-1; D006801:Humans; D010919:Placebos; D011739:Pyrimethamine / Q000627:therapeutic use*; D016781:Toxoplasmosis, Cerebral / Q000209:etiology / Q000517:prevention & control*
D010919:Placebos; D011739:Pyrimethamine
Prévention primaire de la toxoplasmose cérébrale chez le sujet infecté par le VIH: résultats d'un essai randomisé en double insu, pyriméthamine versus placebo. Groupe d'étude Anrs 005/Actg 154.